Search

ZnO is an ideal material for UV detection. However, due to the surface effect of ZnO, the photosensitivity of the ZnO based UV detector needs to be improved. In this study, we deposited a hydroxyl group functionalized (3,4-propylenethiophene) polymer (PProDOT-OH) film onto a hydrothermally grown ZnO nanoarray by electro-chemical deposition method to prevent the corrosion of ZnO by phosphotungsten acid (PWA), and then PWA was drip-coated on the composite film to prepare the ZnO/PProDOT-OH/PWA composite based UV detector. The structure and morphology of the composite were characterized by SEM, UV–vis, FT-IR, XRD, Raman, EDS, XPS analysis, illustrating the phosphotungstic acid was uniformly coated on ZnO/PProDOT-OH surface and confirming the composite was successfully synthesized. The UV detection performance was studied through preparing a UV detector with the composite material and results indicate that the introduction of PWA could enhance the responsivity of the ZnO/PProDOT-OH composite-based UV detector.

Tirofiban is a small non-peptide ligand-mimetic Glycoprotein (GP) IIb/IIIa inhibitor which can reversibly bind to the arginine-glycine-aspartic acid (RGD) recognition site of GP IIb/IIIa to prevent platelet aggregation. It reduces the incidence of thrombotic cardiovascular events in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Although generally considered safe, tirofiban has been reported to be associated with thrombocytopenia in several case reports and clinical trials. The pathogenesis for this adverse reaction is not entirely understood, is thought to be due to immune-mediated reaction. This side effect caused by tirofiban is especially concerning given how frequently it is used in the practice of contemporary cardiovascular care. The present review provides an overview of the pathophysiology, clinical presentation, management, and risk factors associated with tirofiban-induced thrombocytopenia. Tirofiban-induced thrombocytopenia usually occurred within the first 24 h of treatment, frequently accompanied by bleeding symptoms. The majority of the time, supportive care is used to manage this adverse event, and the platelet count often returns to normal in a few days. Although the exact cause of this adverse response is unknown, it is thought to be due to drug-dependent antibodies that bind to GP IIb/IIIa, presumably after tirofiban-induced conformational change. Age ≥ 65 years, white blood cell ≥ 12 × 109/L, diabetes mellitus, congestive heart failure, and chronic kidney disease were identified as the risk factors for tirofiban-induced thrombocytopenia. Further investigations are needed for this. [ABSTRACT FROM AUTHOR]

Context: Paclitaxel (PTX) and carboplatin (CBP) are widely used for the combined chemotherapy of non-small cell lung cancer (NSCLC). However, the development of multidrug resistance of cancer cells, as well as systemic toxic side effects resulting from nonspecific localization of anticancer drugs to non-tumor areas are major obstacles to the success of chemotherapy in treating cancers. Objective: This study aimed to engineer a prodrug-based nano-drug delivery system for co-encapsulate hydrophilic (CBP) and hydrophobic anti-tumor drugs (PTX). This system was expected to resolve the multidrug resistance cause by single drug, and the dual-drug-loaded liposome was also planned to specifically target the cancer cells without obvious influence on normal cells and tissues. Methods: In this paper, PLGA-PEG-CBP was synthesized by the conjugation between the carboxylic group of PLGA-PEG-COOH and the amino group of CBP. Then, self-assembled nanoparticles for combination delivery of PTX and PLGA-PEG-CBP (PTX/CBP NPs) were prepared by solvent displacement technique. Thein vitroandin vivoanti-tumor efficacy was assessed in NCL-H460 human non-small cell lung carcinoma cell line. Results: PTX/CBP NPs achieved the highest cytotoxic effect among all formulationsin vitro, as compared with single drug delivery NPs.In vivoinvestigation on NSCLC animal models showed that co-delivery of PTX and CBP possessed high tumor-targeting capacity and strong anti-tumor activity. Conclusions: The PTX/CBP NPs constructed in this research offers an effective strategy for targeted combinational lung cancer therapy. [ABSTRACT FROM AUTHOR]